Brutalist Biotech

• Two years after Carmot buyout, what’s next for Roche’s expensive obesity pipeline? (2d)
• Chutes & Ladders—CatalYm catalyzes C-suite shakeup (2d)
• Moderna co-founder Robert Langer's son launches new VC with $77.5M, backing from dad (3d)
• Carisma’s lifeline dissipates as reverse merger plans fall through, Moderna cuts ties (3d)
• Biogen strikes $85M Alcyone buyout, securing tech for spinal drug delivery (3d)
• VectorY pens $1.2B biobucks pact to use Shape's capsid to deliver gene therapies into brain (3d)
• Pfizer, Arvinas lose interest in commercializing PROTAC inhibitor, leading to layoffs at the biotech (3d)
• Roche becomes MASH player via $3.5B deal for 89bio and its phase 3 drug (3d)
• QL Biopharm links once-monthly GLP-1 to incumbent-rivaling weight loss in phase 2 (3d)
• ArsenalBio lays off 50% of staff in pivot from early-stage research (3d)
• VC Aditum launches cardiovascular biotech, offers Mabwell up to $1B for siRNA asset (4d)
• J&J's IL-23 drug defeats reigning champ Sotyktu in phase 3 psoriasis trial (4d)
• Regeneron reports phase 3 win in ultra-rare disease, bouncing back to spark race to FDA (4d)
• Lilly rounds out oral GLP-1 weight loss data, posts semaglutide-topping results in diabetes (4d)
• Roivant reports phase 3 autoimmune win for ex-Pfizer asset (4d)
• Why Sanofi's R&D chief is 'pretty pragmatic' about a 'mixed' year of clinical development (4d)
• Innate to lose 30% of workforce, including CSO, in focus on ‘highest-value assets’ (4d)
• Pharma tells Scotland how to court investment amid UK life sciences turmoil (4d)
• Eye disease biotech launches with $100M and sights set on Roche showdown (5d)
• Pharma execs cite ‘challenging’ environment during grilling by UK lawmakers over R&D pullback (5d)

• CDC panel, recast by RFK Jr., softens COVID vaccine recommendations (1d)
• Arvinas reboots, cuts more staff; Porges joins Lazard (2d)
• CDC advisers postpone vote to delay some newborns’ hepatitis B shot (2d)
• CDC panel recommends splitting measles, varicella shots (2d)
• A new biotech venture firm emerges, led by Bob Langer’s son (3d)
• Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs (3d)
• Roche dives into MASH with $2.4B deal for 89bio (3d)
• Fired CDC director says RFK Jr. aims to change childhood vaccine schedule (4d)
• Roivant pill succeeds in rare inflammatory disease trial (4d)
• GSK ups US investment with $30B spending plan (4d)
• Lilly, Novo showcase new obesity drug data; Fasenra falls short in COPD (4d)
• Ollin debuts with $100M and plans to challenge top-selling eye drugs (4d)
• CSL nabs option to acquire a startup and its blood-clotting drug (5d)
• Former CinCor execs reunite to helm new biotech startup (5d)
• ATyr shares plunge on trial miss in inflammatory lung disease (6d)
• A key CDC panel meets this week to discuss vaccines. Here’s what to know. (6d)
• Novartis dives deeper into protein degraders with second Monte Rosa deal (6d)
• Foundation models are medtech’s newest trend. But what are they? (6d)
• Working smarter: best practices for thermal modeling in cold chain packaging design (6d)
• Reaching more patients: How AI and data drive better representation in clinical trials (6d)

• This year’s Endpoints 11 winners; Monarez testifies to Congress; Eli Lilly’s obesity pill lags; and more (1d)
• MapLight prepares for IPO to back schizophrenia, Alzheimer's drug (1d)
• ACIP recommends that people consult a provider before getting Covid shots (1d)
• Merck wins approval of subcutaneous Keytruda, in bid to extend life of world's top-selling drug (2d)
• Regeneron’s Lynozyfic yields 100% response rate in small smoldering multiple myeloma study (2d)
• CHMP recommends Novo's weekly diabetes injection, Bayer's menopause drug (2d)
• CDC vaccine advisors shelve vote on hepatitis B birth dose (2d)
• Endpoints 11 winner 2025: Chai Discovery aims to design drugs on the computer (2d)
• The 2025 winners of the Endpoints 11: Biotech's most exciting startups (2d)
• Endpoints 11 winner 2025: Umoja Biopharma hopes to break CAR-T's in vivo barrier (2d)
• Endpoints 11 winner 2025: Candid Therapeutics builds the next autoimmune powerhouse (2d)
• Endpoints 11 winner 2025: Third Arc's talented team goes after big targets (2d)
• Endpoints 11 winner 2025: Orbis Medicines uses macrocycles to make a biologic-in-a-pill (2d)
• Endpoints 11 winner 2025: Dispatch Bio's ambitious plans for solid tumor cell therapy (2d)
• Endpoints 11 winner 2025: Sironax swings big in neurology as China biotech rises (2d)
• Endpoints 11 winner 2025: Stylus Medicine wants to bring CAR-T to the masses (2d)
• Endpoints 11 winner 2025: Judo Bio broadens the reach of RNA drugs (2d)
• Endpoints 11 winner 2025: Averna Therapeutics wants to harness jumping genes (2d)
• Endpoints 11 winner 2025: Lila Sciences will let 'scientific superintelligence' run the lab (2d)
• Regeneron posts update on its muscle-sparing approach, a new quadruple agonist emerges at #EASD25 (2d)

• ACIP Day 2 Reveals Confusion, ‘Lack of Knowledge,’ on Revamped Committee (1d)
• Bye Bye Bluebird: Gene Therapy Biotech Emerges From Private Buyout With Rebrand (2d)
• Reformed ACIP Recommends Delaying MMRV Combo Vaccination, Forecasts Changes to Hep B, COVID (2d)
• Replimune Crashes as Uncertainty Clouds Regulatory Path for Tumor Destroyer (2d)
• Hope for Rare Pediatric Disease Voucher Reignited as House Bill Passes Committee (2d)
• Nektar Provides More Data for Dermatitis Drug, but Key Questions Remain Unanswered (2d)
• VectorY Bets up to $1.2B+ That Shape’s Brain-Penetrant Capsids Are a Fit (3d)
• Layoffs From Just 6 Pharmas Could Wipe Out Over 39,000 Jobs (3d)
• What Do AI and Hammers Have in Common? (3d)
• Novo, BMS Layoffs Hit New Jersey Hard With More Than 500 Left Jobless (3d)
• Roivant, Pfizer's Therapy Shows ‘Patient-Centered Benefit’ in Rare Inflammatory Condition (3d)
• Lexicon Backs Phase III Go Decision for Non-Opioid Pain Med With Post-Hoc Analysis (3d)
• Roche Makes Major MASH Move With $3.5B 89bio Buy (3d)
• Arsenal, X4 Lay Off Half of Staff to Cut Costs (3d)
• Deep Dive: Oral Obesity Drugs on the Cusp (3d)
• Republicans Ratchet Up Pressure as Monarez Levels Damning Allegations Against Kennedy (3d)
• Webinar: Bridging Formulation & Device | Integrated Supply Chain Strategies for US Pharma Manufacturing (3d)
• Innate Sheds 30% of Staff, Narrows Pipeline Focus Amid ‘Challenging Funding Environment’ (4d)
• FDA’s Ad Crackdown Targets Novo, Lilly’s Oprah Special on GLP-1s (4d)
• FDA Takes Long Overdue Baby Step Toward Regulating Compounder Drug Ads (4d)

• Pro sports leagues should do away with injury reports (6h)
• Winner of mRNA Nobel Prize says ACIP member’s claim that Covid vaccines persist is “absolutely impossible” (1d)
• In a chaotic meeting, RFK Jr.’s handpicked advisers begin altering the childhood vaccine schedule (1d)
• FDA approves ultra-rare disease drug that became a symbol of uncertainty over regulatory standards (1d)
• ACA tax credits still in limbo after stopgap government funding bill fails (1d)
• Federal vaccine panel remade by RFK Jr. votes to maintain insurance coverage for Covid shots (1d)
• CDC reverses telework pause that sparked complaints over its impact on workers with disabilities (2d)
• Up and down the ladder: The latest comings and goings (2d)
• Biotech M&A’s quiet roll (2d)
• We’re reading about CVS coverage of an HIV drug, an EMA boost for Merck, and more (2d)
• Key federal vaccine panel tables vote on delaying newborn hepatitis B shot (2d)
• Federal advisory committee restricts access to MMRV shot by some low-income children (2d)
• What’s at stake after day one of ACIP (2d)
• CDC recommends new Gilead HIV prevention drug, prompting advocates to push CVS for coverage (2d)
• Covid-19 vaccines protect children from severe disease. Here is the evidence (2d)
• Why pharma companies are suddenly pausing investment in the U.K. (2d)
• FDA takes on GLP-1 compounding boom with warnings about misleading marketing (2d)
• I’m a doctor — and I introduce myself by my first name (2d)
• Trump administration to close Miami organ donation group it calls ‘failing’ (2d)
• Trump administration’s new global health aid strategy focuses on bilateral deals with countries (2d)

• Trially AI Raises $4.7M Seed Round, Launches AI for Clinical Trial Enrollment (3h)
• Helmholtz Munich and Parse Biosciences Partner to Build Largest Human Lung Tissue Perturbation Atlas (2d)
• Immuto Raises $8M Seed for AI Structural Surfaceomics, Enters Daiichi Sankyo Oncology Collaboration (2d)
• T.Rx Capital Raises $77.5M to Back Early-Stage Biotech and Digital Health (3d)
• Enveda Starts Phase 1b of AI-Discovered Small-Molecule Anti-Inflammatory for Atopic Dermatitis (3d)
• UK Health-AI Push: NVIDIA Partnerships Back Sovereign Models from Imaging to Drug Design (3d)
• Stanford–Arc Team Reports AI-Made Viruses That Kill Bacteria (3d)
• Google-Backed BenchSci Reports New System to Extract Experimental Context From Biomedical Papers Into a Traceable Evidence Graph (4d)
• Lantern Pharma Reports AI-Guided LP-184 Meets Phase 1a Endpoints in Solid Tumors (4d)
• Biomni and Sage Partner on AI-Powered Access to Biomedical Data (4d)
• Causaly Introduces Agentic Research AI Platform For Life Sciences RD (4d)
• datma Launches Federated Biomarker Explorer for Health Systems (5d)
• Medra Launches AI-Driven Platform for Continuous Scientific Experimentation (5d)
• Google’s AI Auto-Writes Reproducible Research Software for Genomics and COVID Forecasting (6d)
• Lila Sciences Raises $235M to Build Autonomous AI Labs, Joins Unicorn Ranks (6d)
• Lila Sciences Raises $235M to Expand AI-Driven Autonomous Science Platform (6d)
• Phesi Reports GLP-1 Trials Now Span 100+ Diseases (6d)
• Tempus AI Validates RNA-Based Algorithm for Pancreatic Cancer Therapy Selection (6d)
• XtalPi and PharmaEngine Get Approvals for Phase I Trial of AI-Designed PRMT5 Inhibitor (1w)
• Oracle, AMD and Absci Collaborate to Scale AI-Driven Drug Discovery (1w)

Drug Channels

• Cracking the Code of BIN/PCN/Group Data for Faster Benefit Verification (2d)
• Preorder Now: DCI’s 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors (4d)
• Inside the 2025 PSAO Market: How Wholesalers Shape Pharmacy–PBM Relationships (5d)
• The $90 Billion Leakage Problem: How RIS Rx Helps Pharma Recover Lost Revenue (6d)
• Inside Rare Disease Pharmacy: Lessons in Personalizing Care (1w)
• Drug Channels Leadership Forum 2026: Full Agenda Now Available (Spoiler: Even more awesome than 2025!) (2w)
• If Banks Sync Data in Real Time, Why Can't Patient Services? (2w)
• Hubs: The Bridge Between Patients and Providers (3w)
• Why the Pharmacy Supply Chain Is Broken and How SmithRx Is Fixing It (1mo)
• Drug Channels News Roundup, August 2025: White Bagging Battles, Private Label Price Hypocrisy, 340B Patient Problems, and UnitedHealth Group’s Woes (1mo)
• Solving the Gross-to-Net Bubble With Better Data (1mo)
• Solving the Gross-to-Net Bubble with Better Data (1mo)
• Pharmacy Shakeout: Why U.S. Drugstores Are Disappearing (1mo)
• Patient Support’s Perfect Storm in 2025: Hits, Misses, and Surprises (1mo)
• Markup Madness 2025: Hospitals, Insurers, and the Broken Buy-and-Bill Market for Biosimilars (1mo)
• The AI Advantage: Evolving Patient Engagement Strategies to Improve Outcomes (1mo)
• Drug Channels News Roundup, July 2025: 340B vs. Patients, Humira Whiplash, Accumulator Fallout, and Pharmacy Struggles (1mo)
• Beyond Throughput: Building Reverification Strategies That Safeguard Access (2mo)
• 2024 Gross-to-Net Realities at 9 Top Drugmakers: A New Era of Market Access (2mo)
• Informa Connect’s Medicaid Drug Rebate Program Summit (2mo)

• Genfit SA discontinues lead programme (10h)
• Mondego Bio raises €20m in Series A (2d)
• Whitepaper Plastic Injection Molding in Cleanrooms (2d)
• Roche acquires 89bio for US$3.5bn (3d)
• CSL backs VarmX in US$2.2bn deal (4d)
• Enhanced Genomics raises US$19m (4d)
• Monte Rosa Therapeutics and Novartis agree on second billion-dollar deal (5d)
• Trump dismantles FDA expert committees (6d)
• UK pharma lobby warns of crisis in British life sciences (1w)
• A Universal Solution Emerges: Anti-Linker Antibodies Simplify CAR-T Detection and Development (1w)
• Alchemab Therapeutics reports US$32m Series A extension (2w)
• Servier acquires Kaerus Bioscience’s FXS candidate for US$450m (2w)
• NRG Therapeutics Ltd bags £50m in Series B financing (2w)
• BioFlo® 120 – Performance Meets Value (2w)
• BioNTech‘s breast cancer ADC outperforms Roche’s Kadcyla (2w)
• Alt protein: EASAC sees immediate need for action (2w)
• Microbiome play MRM Health NV raises €55m in Series B (2w)
• Novartis AG invests US$200m in lacklustre Parkinson’s target (3w)
• Cytokinetics’ Aficamten with breakthrough Phase III results (3w)
• Polpharma Biologics secures distribution of upcoming biosimilars (3w)

Drug Hunter

• August 2025 (2d)
• BMS-986463 (2d)
• MOMA-341 (3d)
• MRGPRX2 in Immunology - Why is the Field Heating Up? (4d)
• CK-4021586 (5d)
• zolucatetide (FOG-001) (6d)
• Drug-Induced Phototoxicity (6d)
• Basic Pharmacokinetic Principles (1w)
• NVP-IID432 (1w)
• PF-07899895 (1w)
• PF-07293893 (2w)
• Lessons in LAI: Discovery of a Long-Acting Injectable TAK1 Inhibitor (2w)
• Glossary: AI for Drug Discovery (2w)
• Cracking the Entry Code: CD36 as a Key Receptor for Heterobifunctional Degrader Cellular Uptake (2w)
• PF-07853578 (2w)
• darovasertib (NYP-LXS196, IDE-196) (2w)
• Drug-Induced Phospholipidosis (3w)
• sevabertinib (BAY 2927088) (3w)
• zongertinib (BI 1810631) (3w)
• Opposing Views of the Immunology Target NEK7 (3w)

• GLP-1 drugs on WHO Essential Medicines List: what’s the impact? (2d)
• BIOSPAIN 2025: Why 1000 companies from more than 40 countries will gather in Barcelona this year (2d)
• Budget blues: where are cell and gene therapies heading? (4d)
• 10 biotech companies in China you should know about (5d)
• Tapping into the regulatory goldmine: Interview with Ruxandra Teslo (6d)
• Eight biotech career paths where demand is skyrocketing (1w)
• AION Labs is building innovative biotechs with top pharma partners in Israel (1w)
• Kriya Therapeutics has raised $900 million, but for what? (2w)
• When rare diseases are not so rare after all: A closer look at where and why this happens (2w)
• Top biotech deals in August 2025 (2w)
• Advanced expression vector design to overcome challenges in developing multichain biotherapeutics (2w)
• With Lykos CRL now public, FDA opens new era of accountability (2w)
• Closing treatment gaps in yellow fever: are germ-free egg-based vaccines the answer? (2w)
• Navigating the biotech development journey from first steps to global scale with Lonza (2w)
• Radiopharma’s big year: Interview with RadioMedix CEO Dr. Delpassand (3w)
• How are biotechs tackling malaria? (3w)
• The biggest biotech funding rounds in August 2025 (3w)
• Blood Cancer Awareness Month: What biotech holds in store (3w)
• Can genetically modified crops help us adapt to climate change? (3w)
• A Finnish biotech is making progress on Parkinson’s disease with support from The Michael J. Fox Foundation (3w)

Bio IT World

• NIST Calls for Researchers to Test mRNA Research Grade Test Material (3d)
• Canadian Researchers Measure Insulin Levels for Early Signs of Diabetes, Obesity (4d)
• Drug Delivery Platform Could Usher Phage Therapeutics to the Clinic (5d)
• How The New European Health Data Space Will Drive The Development Of AI-Based Tools (1w)
• Illumina’s Commercial Launch of Proteomics Assay, Acquisiton of SomaLogic (2w)
• First-in-Class Dietary Supplement a Potentially Big Win for Babies (2w)
• Microbiome-Based Therapies Hold Promise for Chronic Diseases (2w)
• Psilocybin Being Investigated as an Anti-Aging Agent (3w)
• Machine Learning Penetrance Score Predicts Genetic Variant Impacts (3w)
• Ultima’s ppmSeq Pushes Sequencing to New Levels of Accuracy (3w)
• Follow the Money: Rheumatoid Arthritis Therapy, Novel Next-Gen Biosensor, More (4w)
• BioMed X, Novo Nordisk Collaboration, 10x Genomics Launches Platform Addition, More (4w)
• Bioprocessing Summit Honors LISURE as Best of Show Winner (1mo)
• Family-Based Genomics Benchmark Promises More Accurate Variant Detection (1mo)
• Nature’s Most Promising Bioactives to Speed Up Evidence-Based Drug Discovery (1mo)
• Open-Source Medical Device Platform Aims to Accelerate Time to Market (1mo)
• AI-Powered Cell Mapping Platform Accelerates Biotech Research and Drug Development (1mo)
• AI in Medicine Making and Healthcare: Finding the Balance (1mo)
• Russia Targets National Database of 1 Million Genomes by 2030 (1mo)
• New Research and Pipeline Updates at Alzheimer’s Conference (1mo)

• Cellares and Technology Provider Team Plan to Expand Cell Q’s Capabilities for Commercial Scale Cell Therapy QC (2d)
• Pancreatic Cancer Slowed by Boosting Cell Surface Sugar in Mice (2d)
• Process Intensification Drives Innovation in Analytical Technologies (2d)
• CRISPR Activation Restores SCN2A Loss, Improves Neurodevelopmental Outcomes in Mice (2d)
• Oral Microbiome Linked to Future Risk of Pancreatic Cancer (2d)
• Boston’s Bioprocessing Buzz: GEN Reports Live from BPI 2025 (3d)
• Needle-Free Vaccine Delivery Enabled by Stretching the Skin (3d)
• Malaria-Transmitting Mosquito’s Genetic Diversity and Evolution Revealed (3d)
• Organoids Recreate Native Kidney Architecture to Model Complex Disease in Mice (3d)
• Optimizing Chromatography for Therapeutic-Antibody Processing (3d)
• Accelerated Downstream Development of Viral Vectors (3d)
• Intensified Fed-Batch for Reshaping Biologics Manufacturing (3d)
• Streamlining Residual Host Cell Impurity Monitoring (3d)
• Collaboration Key to First Personalized mRNA-based CRISPR Therapy (3d)
• AI Designs Viable Bacteriophage Genomes, Combats Antibiotic Resistance (4d)
• “Creeping Fat” Triggers Debilitating Scarring in Crohn’s Disease (4d)
• CRISPR Mouth-Swab Test Could Transform Tuberculosis Screening (4d)
• Lilly Chooses Virginia Site for $5B API Manufacturing Facility, with ADCs in Mind (4d)
• Genome Assembly of Human Epithelial Cell Line Completed at Reference Quality (4d)
• Novartis Inks Up-to-$5.7B Second Collaboration with Monte Rosa (4d)

• MDS Treatment Advances: Targeted Therapies and Anemia Management (3h)
• For Young Adults, A Cancer Diagnosis ‘Doesn’t Define Who You Are’ (23h)
• Lung Cancer Can Affect Anyone, Even Non-Smokers (23h)
• Advances in Kidney Cancer Allow Less Invasive and More Personalized Care (1d)
• MNV-201 Secures FDA Fast Track Designation in Myelodysplastic Syndrome (1d)
• Non-Melanoma Skin Cancer: An Overview From Diagnosis to Treatment (1d)
• FDA Approves Subcutaneous Keytruda in Adult and Pediatric Solid Tumors (2d)
• Welcome to a Survivor’s Yard (2d)
• A Patient Guide to Understanding HER2-Positive Breast Cancer (2d)
• Vaccine Elicits Immune Responses in Pancreatic Cancer (2d)
• Accurate Kidney Cancer Diagnosis is Key to Effective Treatment (2d)
• What Does Standing Up to Cancer Mean to You? (2d)
• From Patient to Author: Emphasizing Shared Decision Making in NSCLC (2d)
• Understanding Your Diagnosis: An Overview of Leukemia (3d)
• Looking Back on the Shock of a Multiple Myeloma Diagnosis (3d)
• Beyond the Diagnosis: A Stage-by-Stage Guide to Multiple Myeloma Treatment (3d)
• FDA Approves Bosaya and Aukelso Biosimilars for Solid Tumor Care (3d)
• How to Access Support Resources for Rare Cancers (3d)
• The Defining Moments of Support After Hearing ‘You Have Cancer’ (3d)
• Off-the-Shelf Immunotherapy May Offer Benefits in Kidney Cancer (3d)

Contract Pharma*

• Powering Global Access Through an Integrated Supply Chain Infrastructure (2d)
• Roche to Acquire 89bio and Phase 3 MASH Candidate in Potential $3.5B Deal (3d)
• Kindeva Opens New UK HQ and Manufacturing Site (3d)
• Cellares Selects Technology Providers to Expand Cell Q’s Capabilities (3d)
• Wheeler Bio to Support MindImmune’s Alzheimer’s Prevention Program (3d)
• Mabwell Bioscience, Aditum Bio Form Kalexo Bio (3d)
• GSK to Invest $30B in R&D and Manufacturing in the U.S. (3d)
• Quotient Sciences, CPI Form RNA Drug Development Joint Venture (4d)
• Altasciences Recognized for Small Molecule Dosage Form CDMO Services (4d)
• Simtra Purchases 65-Acre Property in Indiana (4d)
• Lilly to Invest $5B in New Virginia Plant (5d)
• Parexel Taps Rob Goodwin as COO (5d)
• ProBioGen to Operate GMP Manufacturing Operation at Berlin Center for Gene & Cell Therapies (5d)
• CSL Enters Strategic Collaboration with VarmX for VMX-C001 (5d)
• Piramal Pharma Solutions Acquires Korsch XM-12 Bilayer Tablet Press (5d)
• Carolina Molecular, Astoriom Partner to Provide Molecular Testing & Biospecimen Storage Services (5d)
• GAIASO Appoints Tracey Brown Chief Executive Officer (5d)
• Takeda to Transport Products Between Europe and the U.S. with Sailing Cargo Vessels (5d)
• Monte Rosa & Novartis Partner to Develop Immune-Mediated Disease Treatments (6d)
• FUJIFILM Biosciences Introduces BalanCD HEK293 Perfusion A Medium (6d)

• European Commission approves ROMVIMZA for TGCT treatment (3d)
• Modus data on sevuparin for CKD to be presented at global GAG symposium (3d)
• Bimekizumab shows sustained three-year efficacy in hidradenitis suppurativa (4d)
• Nxera and Cancer Research UK begin phase 2a trial of HTL0039732 (4d)
• Imfinzi approved for NHS use in limited-stage small cell lung cance (5d)
• Vorasidenib approved in UK for treating IDH-mutant brain tumours (5d)
• SOM Biotech receives EMA backing for Huntington’s disease drug (6d)
• Capvaxive shows strong immune response in children at risk of pneumococcal disease (1w)
• Lundbeck unveils migraine data for eptinezumab at international congress (1w)
• Rezatapopt shows promise in phase 2 trial for TP53 Y220C solid tumours (2w)
• Quotient Sciences and CPI launch RNA drug development venture (2w)
• Bluejay begins phase 3 trial of brelovitug for hepatitis D (2w)
• Eisai unveils promising phase 1b data for narcolepsy drug E2086 (2w)
• AlzeCure presents phase 2 data on ACD440 at NeuPSIG 2025 (2w)
• Resolution Therapeutics doses first patient in EMERALD study of RTX001 (3w)
• Resolution Therapeutics doses first patient in EMERALD study of RTX001 (3w)
• Polpharma Biologics and MS Pharma partner to expand biosimilar access (3w)
• eXmoor and Anthony Nolan partner to streamline cell therapy development (3w)
• FDA approves LEQEMBI IQLIK for maintenance dosing in early Alzheimer’s disease (3w)
• Lilly receives UK approval for pirtobrutinib in relapsed blood cancers (3w)

• For Many, CAR T is a Miracle Therapy – We Need to Get it to More Patients (3h)
• Leading Quality Care When The Odds Are Stacked Against You (4h)
• What’s Top of Mind for 3 Healthcare Execs on Deploying AI (1d)
• Scaling Virtual Care Is Both a Moral and Financial Imperative, Sanford Health Exec Says (1d)
• Two Is Better Than One: Startup Dualitas Lands $65M to Bring Bispecific Drugs to Autoimmune Disease (1d)
• Why We Need to Rethink Private Practice Mental Health Care (2d)
• The Truth About Portals: Why Is Patient Usage so Low? (2d)
• The Top-Ranked Private Cord Blood Banks in the U.S. (2d)
• AI in Healthcare: Investors’ Green and Red Flags Among Startups (2d)
• Roche’s Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio Acquisition (3d)
• Why Insurers Need to Lead in the Shift to Healthcare Consumerism (3d)
• What Self-Insured Employers Should Look for in a Digital Health Vendor (3d)
• Behind “Rise of Malingering” in ER Psychiatry: Why Better Patient Classification Matters (3d)
• Do You Value MedCity News? Take Our Survey! (3d)
• Lōvu Health Rakes In $8M for Maternal Health Platform (3d)
• Inside Duke’s Approach to Building and Buying AI Tools (3d)
• GSK Plans to Spend $30B on U.S. Manufacturing and R&D Infrastructure Over the Next 5 Years (3d)
• The Delegation Dilemma: Why It’s Time for Health Plans to Rethink Vendor-Managed Utilization Management (4d)
• Addressing the Primary Care Crisis by Integrating Advanced Practice Providers (APPs) (4d)
• The Top EAP Companies for Mental Health Support (4d)

• CDC committee endorses restrictions on COVID-19 vaccines (1d)
• Preventing radiation damage with melanin-based material (2d)
• This chemist aims to change the game for species conservation (2d)
• CDC advisers endorse changes to MMR, varicella vaccine schedules (2d)
• Quiz: How much do you know about sleep aids? (2d)
• National Academies’ climate report supports endangerment finding, contradicting EPA (2d)
• 2025 Ig Nobel Prizes (2d)
• Breakthrough Energy sees a path through green chemistry's desert (2d)
• Preparing to be in person (3d)
• Syensqo CEO Ilham Kadri to step down (3d)
• Ousted CDC director details firing, warns of vaccine schedule changes (3d)
• Premature deaths from wildfire smoke exposure are set to rise (3d)
• GSK and Lilly to spend billions on US manufacturing (3d)
• Chemistry in pictures: Bespoke particle accelerator (3d)
• Congress pushes back on Trump’s proposed cuts to NSF (4d)
• Inside the 20-year search for dinosaur proteins (4d)
• Can New Jersey’s $2 billion PFAS deal with DuPont be a model? (4d)
• CAS and PetroChina Shanghai Advanced Materials Research Institute partner to innovate on advanced materials (4d)
• Mystery solved: Jackson Pollock used manganese blue in famous 1948 painting (4d)
• Ollin eyes ophthalmologic diseases with $100 million launch (4d)

The Pharma Letter*

• The week in pharma: action, reaction and insight – week to September 19 (5h)
• FDA approves Merck’s Keytruda Qlex (1d)
• FDA accelerated approval for first treatment for Barth syndrome (1d)
• AI-first is not a strategy. It’s how the next generation of pharmaceuticals will operate (2d)
• Aspire Pharma (2d)
• Latest batch of new meds backed for approval by EMA/CHMP (2d)
• EADV data shows Ilumetri’s ‘significant value in long-term holistic management of psoriasis’ (2d)
• Celltrion updates on availability of Omlyclo across Europe (2d)
• Torii Pharma gains Japanese approval for Ycanth (2d)
• FDA delivers three new HAE drugs after four-year drought (2d)
• Biotechs bet big on NF-κB pathway despite history of setbacks (2d)
• Biotechs bet big on NF-κB pathway despite history of setbacks (2d)
• Swiss approval for Idorsia’s Jeraygo (2d)
• Conditional approval for Izervay in Japan (2d)
• ACIP meeting adds to uncertainty over US vaccination policy (2d)
• Sobi and Ionis win EU approval for Tryngolza in FCS (2d)
• Replimune lacks clear pathway in melanoma after FDA meeting (2d)
• Ozempic bests dulaglutide in reducing heart attack, stroke and death risk (2d)
• Otsuka gains approval for Nexletol in Japan (2d)
• VectorY secures option to use Shape’s AAV capsid (2d)

• Potential of Invariant Natural Killer T Cells Spurs Advances in AML (2h)
• Physicians Are Urged to Reclaim Listening as a Clinical Skill (1d)
• Minimal Residual Disease Testing Gains Traction in CLL and Multiple Myeloma (1d)
• Dr Burke on MRD Testing in CLL and Myeloma (1d)
• FDA Approves SC Pembrolizumab for Solid Tumor Indications (2d)
• FDA Fast Tracks MNV-201 in Myelodysplastic Syndromes (2d)
• Larotrectinib Shows Robust Efficacy and Safety in TRK Fusion Cancer (2d)
• DeLLphi-303 Study: Tarlatamab's Impact on Small Cell Lung Cancer (2d)
• FDA Approval Path Remains Unclear for RP1 in Melanoma (2d)
• Carotuximab Shows Promising Early Efficacy in Advanced Prostate Cancer (2d)
• ADG126 Exhibits Clinical Meaningful Efficacy in MSS CRC (2d)
• Long-Term BPDCN Data Show Potential for Durable CRs and Transplant (2d)
• Vision-Saving Surgical Technique Linked to Survival Benefit in Uveal Melanoma (3d)
• Prostate Cancer Awareness Month: Exciting Developments (3d)
• Plixorafenib Demonstrates Clinical Benefit in Thyroid Cancer (3d)
• Prostate Cancer Awareness Month: Unmet Needs (3d)
• Ateganosine Plus Cemiplimab Extends PFS Beyond Standard of Care in NSCLC Trial (3d)
• Sacituzumab Govitecan Shows Antitumor Activity in Metastatic Cervical Cancer (3d)
• Exploring Differences in Survival With Lenvatinib in Recent HCC Trials (3d)
• Improved Survival Observed in CABINET Trial of Pancreatic NETs (3d)

• Reviewers Behaving Badly (1d)
• Mirror Life Worries (2d)
• More Legislation to Watch (4d)
• Tuberculosis Defenses (5d)
• Cellular Longevity Through Stress (1w)
• Life, Maybe, On Mars, Unless We Change Our Minds (1w)
• Degunkification (2w)
• Silent RNA (2w)
• An Underappreciated Fate of Drugs in Vivo (2w)
• Stirring Bars are Superstition? (2w)
• Nuclear Fusion in Palladium Metal. No, Really. (2w)
• A Condensate Dissolver (3w)
• RFK Jr. Must Go. And He's Not the Only One. (3w)
• Go Make Me Fifty Kilos of This Stuff (4w)
• Lithium Orotate Revisited (4w)
• When Do You Need a Macrocycle, Anyway? (4w)
• Cranking Up Protein Expression to the Limit (1mo)
• Carbamorphine And More (1mo)
• Kakistocracy (1mo)
• Journal Impact Nonsense (1mo)

• Breaking: ACIP pushes back vote on hepatitis B vaccine (2d)
• Biogen buys CNS delivery specialist Alcyone Therapeutics (2d)
• Closed Loop Medicine launches digital GLP-1 dosing platform (2d)
• Lila Sciences' $235m first round, and other biofinancings (2d)
• UK specialists call for more testing on psychedelics (2d)
• ACIP votes against first-dose MMRV for under 4s (2d)
• Regeneron drug on track to be second FOP treatment (3d)
• electronRx cues up launch of digital respiratory platform (3d)
• Oral GLP-1 contest ramps up with new Novo Nordisk data (3d)
• Roche poised to buy MASH drug developer 89bio for $3.5bn (3d)
• Monarez: Kennedy has plan to change child vaccine schedule (4d)
• Lilly weakens on data reveal for oral obesity candidate (4d)
• PHTI delivers its verdict on DHTs for opioid use disorder (4d)
• As Trump visits UK, GSK pledges $30bn in US investment (4d)
• AZ's bid for Fasenra approval in COPD falls short (4d)
• Flood of warning letters follows DTC ad clampdown (4d)
• Study finds Novo's Wegovy turns down 'food noise' (5d)
• Imfinzi becomes first NHS drug for aggressive lung cancer (5d)
• FDA's Makary explains 'overdue' pharma ads crackdown (5d)
• RFK Jr expands ACIP ahead of highly anticipated meeting (5d)

• This week in Drug Discovery (15 – 19 September) (2d)
• DDW Fall issue out now (2d)
• DDW Highlights: 19 September 2025 (2d)
• DDW Fall 2025 (2d)
• First patient dosed in Phase I trial of antibody-drug conjugate TJ101 (2d)
• Agreement opens new pathways for Lithuanian life science scale-ups (2d)
• Enhanced Genomics receives new funding worth $19 million (2d)
• Study finds safer alternative to CRISPR (2d)
• What’s next for dementia drug research and development? (2d)
• Great Ormond Street Hospital Charity joins cancer research consortium (3d)
• UCB publishes new data on clinical trials for galvokimig (3d)
• Financing round paves way for AecorBio to investigate FT-002a (3d)
• New data sheds light on immunotherapy failure in cancer patients (3d)
• Abzena announces expansion of its cell line development platform (3d)
• FDA cracks down on overseas cell processing for clinical trials (3d)
• Webinar: Maximise the capabilities of spatial biology (3d)
• Whitepaper: How protein biomarkers can impact cancer outcomes (4d)
• Learn about protein biomarkers shaping cancer outcomes in the tumour microenvironment (4d)
• GSK to invest $30 billion in US over next five years (4d)
• State-of-the-art life sciences hub opened in London (4d)